alexa Multi Drug Resistant Shigella flexneri An Emerging Thre


Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Multi Drug Resistant Shigella flexneri An Emerging Threat to Community

 
To read the full article Peer-reviewed Article PDF image

Abstract

Shigellosis remains to be a considerable public health problem in many parts of the world and is endemic in India. Among the different studies conducted across India the isolation rate of Shigella varies from 2-6%, with Shigella flexneri to be the most prevalent serogroup. Unlike other acute diarrheal illness that require adequate fluid replacement (oral or intravenous), shigellosis additionally needs antimicrobial therapy to curtail the duration of illness and to prevent transmission to the close contacts. But like many other bacterial pathogens the frequency of antibiotic resistance among Shigella species is on the rise, and emergence of multi drug resistance (MDR) Shigella is a growing concern globally. The third generation cephalosporins and the fluoroquinolones are the mainstay of treatment in MDR cases, however emergence of strains resistant to even these drugs have been reported worldwide and also from various parts of India. Additionally strains of Shigella spp. that produce extended spectrum β-lactamase (ESBL), conferring resistance to third generation cephalosporins have also been reported thus limiting the treatment options for clinicians. We here report a case of 43 years old man suffering from diarrhea due to MDR strain of Shigella flexneri found resistant to all cephalosporins (1st, 2nd, and 3rd generation) and fluoroquinolones, susceptible only to meropenem, cefoperazone-sulbactam and piperacillin-tazobactam. Though the patient was treated successfully, but spread of such clones may pose a greater threat to the community and a comprehensive strategy for resistance control involving regulation of drug availability, antimicrobial drug quality assurance and discouraging antimicrobial abuse needs to be evolved.

Keywords

Recommended Journals

Share This Page

Additional Info

Loading
Loading Please wait..
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords